Fluctuations in circulating cell-free mitochondrial and nuclear DNA copy numbers in blood plasma after anti-tuberculosis drug intake in patients with drug-susceptible tuberculosis.

Fluctuations in circulating cell-free mitochondrial and nuclear DNA copy numbers in blood plasma after anti-tuberculosis drug intake in patients with drug-susceptible tuberculosis.

Publication date: Mar 01, 2025

Biomarker research characterising the effect of anti-tuberculosis (TB) chemotherapy on systemic body response is still limited. In this study, we aimed to investigate fluctuations in circulating cell-free mitochondrial DNA (ccf-mtDNA) and circulating cell-free nuclear DNA (ccf-nDNA) copy number (CN) in blood plasma of patients with drug-susceptible TB (DS-TB) and to decipher factors related to these fluctuations. The results showed considerable changes in ccf-mtDNA CN in plasma samples before drug intake and 2 and 6 h afterwards, with high inter patient variability at each time point. Multivariate linear regression revealed that the dynamics of ccf-mtDNA CN was influenced by patients’ age, ethambutol pharmacokinetics, and body-mass index (BMI); ethambutol exposure emerged as the most significant factor. Very low ccf-nDNA CN in all three time points with little variation was observed; none factors were strongly associated with ccf-nDNA. In conclusion, our study revealed the effect of anti-TB chemotherapy, age and BMI on acute changes in circulating ccf-mtDNA CN in blood plasma and highlighted the systemic, mitochondria-related effects of ethambutol in patients with TB. Further studies with larger cohorts are needed to understand the biological relevance of ccf-DNA in patients with TB and to validate its application in TB treatment monitoring.

Open Access PDF

Concepts Keywords
Chemotherapy Adult
Dna Age Factors
Free Aged
Pharmacokinetics Antitubercular Agents
Plasma Antitubercular Agents
Biomarkers
Biomarkers
Body Mass Index
Cell Nucleus
Cell-Free Nucleic Acids
Cell-Free Nucleic Acids
DNA, Mitochondrial
DNA, Mitochondrial
Ethambutol
Ethambutol
Female
Humans
Male
Medication effects
Middle Aged
Mycobacterium tuberculosis
Pharmacokinetics
Time Factors
Treatment Outcome
Tuberculosis
Tuberculosis
Young Adult

Semantics

Type Source Name
disease IDO cell
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Ethambutol
disease MESH Lung Diseases
disease MESH latent infection
disease IDO blood
drug DRUGBANK Coenzyme M
pathway REACTOME Apoptosis
disease MESH physiological stress
disease MESH infectious diseases
disease MESH critical illnesses
disease MESH minimal residual disease
disease MESH chronic infection
disease MESH infection
disease MESH COVID 19
disease MESH Parkinson disease
pathway KEGG Parkinson disease
disease MESH major depressive disorder
disease MESH sepsis
disease MESH co infection
disease MESH hepatitis
disease IDO immunodeficiency
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
drug DRUGBANK Pyrazinamide
drug DRUGBANK Edetic Acid
disease IDO assay
drug DRUGBANK Water
disease MESH hypertension
disease MESH concomitant conditions
disease MESH diabetes mellitus
disease MESH asthma
pathway KEGG Asthma
disease MESH epilepsy
drug DRUGBANK Azelaic acid
disease MESH Underweight
disease MESH Overweight
disease MESH chronic conditions
drug DRUGBANK Hyaluronic acid
disease MESH oxidative stress
pathway REACTOME Autophagy
disease MESH necrosis
disease MESH psychological stress
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
pathway KEGG Circadian rhythm
drug DRUGBANK Creatinine
drug DRUGBANK Iron
drug DRUGBANK Copper
disease MESH optic neuropathy
drug DRUGBANK Oxygen
drug DRUGBANK ATP
disease MESH obesity
disease MESH inflammation
pathway REACTOME Innate Immune System
disease IDO quality
disease MESH clinical relevance
disease IDO facility
disease MESH latent tuberculosis infection
disease MESH pulmonary tuberculosis
disease MESH tumor
disease MESH acute ischemic stroke
disease MESH axial spondyloarthritis
disease MESH septic shock
disease IDO bacteria
disease IDO host
pathway REACTOME Metabolism
disease IDO susceptibility
drug DRUGBANK Deoxy-2-Fluoro-B-D-Cellotrioside
disease MESH mitochondrial dysfunction
pathway REACTOME Release
disease MESH insulin resistance
pathway KEGG Insulin resistance
drug DRUGBANK Guanosine
pathway KEGG Platelet activation

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *